Nintedanib is active in vivo, its effects observed as decreased vessel density and integrity and significant growth inhibition [2]. Nintedanib is rapidly metabolised to BIBF-1202 [4]. We have tagged FLT4 (VEGFR-3) as this drug's primary molecular target for data metrics purposes only. We fully acknowledge the multi-targeted nature of nintedanib and include reported kinase interactions in the table below.